Phaseline

Companies › Newron Pharmaceuticals

Newron Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Evenamide
Sodium channel alpha subunit blocker
Ion channelsPhase 3Treatment-resistant SchizophreniaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07184619EvenamidePhase 3Treatment-resistant SchizophreniaPsychiatryMar 2027

Targets

Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines HB BioTech Encoded Therapeutics Biohaven Therapeutics TLC Biopharmaceuticals Shenzhen Ausa Pharmed Grace Therapeutics LXO Ireland Jiangsu HengRui Medicine

Companies built like this

Xenon Pharmaceuticals HB BioTech Gedeon Richter Cybin IRL Beijing Union Pharmaceutical Factory

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.